361 related articles for article (PubMed ID: 23784159)
1. Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.
Ryan GJ; Moniri NH; Smiley DD
Am J Health Syst Pharm; 2013 Jul; 70(13):1123-31. PubMed ID: 23784159
[TBL] [Abstract][Full Text] [Related]
2. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
3. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.
DeYoung MB; MacConell L; Sarin V; Trautmann M; Herbert P
Diabetes Technol Ther; 2011 Nov; 13(11):1145-54. PubMed ID: 21751887
[TBL] [Abstract][Full Text] [Related]
4. [Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy].
Lecube A; Bueno M; Suárez X
Med Clin (Barc); 2014 Sep; 143 Suppl 2():23-7. PubMed ID: 25437462
[TBL] [Abstract][Full Text] [Related]
5. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
Buse JB; Bergenstal RM; Glass LC; Heilmann CR; Lewis MS; Kwan AY; Hoogwerf BJ; Rosenstock J
Ann Intern Med; 2011 Jan; 154(2):103-12. PubMed ID: 21138825
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.
Inagaki N; Atsumi Y; Oura T; Saito H; Imaoka T
Clin Ther; 2012 Sep; 34(9):1892-908.e1. PubMed ID: 22884767
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.
Malloy J; Meloni A; Han J
Postgrad Med; 2013 May; 125(3):58-67. PubMed ID: 23748507
[TBL] [Abstract][Full Text] [Related]
8. Summaries for patients: Does adding exenatide to insulin treatment benefit patients with type 2 diabetes?
Ann Intern Med; 2011 Jan; 154(2):I-40. PubMed ID: 21135289
[No Abstract] [Full Text] [Related]
9. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
Bergenstal RM; Wysham C; Macconell L; Malloy J; Walsh B; Yan P; Wilhelm K; Malone J; Porter LE;
Lancet; 2010 Aug; 376(9739):431-9. PubMed ID: 20580422
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
Russell-Jones D; Cuddihy RM; Hanefeld M; Kumar A; González JG; Chan M; Wolka AM; Boardman MK;
Diabetes Care; 2012 Feb; 35(2):252-8. PubMed ID: 22210563
[TBL] [Abstract][Full Text] [Related]
11. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.
Norwood P; Liutkus JF; Haber H; Pintilei E; Boardman MK; Trautmann ME
Clin Ther; 2012 Oct; 34(10):2082-90. PubMed ID: 23031623
[TBL] [Abstract][Full Text] [Related]
12. Once weekly exenatide: efficacy, tolerability and place in therapy.
Wysham C; Grimm M; Chen S
Diabetes Obes Metab; 2013 Oct; 15(10):871-81. PubMed ID: 23425609
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
14. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.
Wysham C; Bergenstal R; Malloy J; Yan P; Walsh B; Malone J; Taylor K
Diabet Med; 2011 Jun; 28(6):705-14. PubMed ID: 21434995
[TBL] [Abstract][Full Text] [Related]
15. Managed care perspective on three new agents for type 2 diabetes.
VanDeKoppel S; Choe HM; Sweet BV
J Manag Care Pharm; 2008 May; 14(4):363-80. PubMed ID: 18500914
[TBL] [Abstract][Full Text] [Related]
16. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.
Diamant M; Van Gaal L; Guerci B; Stranks S; Han J; Malloy J; Boardman MK; Trautmann ME
Lancet Diabetes Endocrinol; 2014 Jun; 2(6):464-73. PubMed ID: 24731672
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
Gu S; Wang X; Qiao Q; Gao W; Wang J; Dong H
Diabetes Obes Metab; 2017 Dec; 19(12):1688-1697. PubMed ID: 28452095
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.
Gadde KM; Vetter ML; Iqbal N; Hardy E; Öhman P;
Diabetes Obes Metab; 2017 Jul; 19(7):979-988. PubMed ID: 28205322
[TBL] [Abstract][Full Text] [Related]
19. Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.
King AB; Montanya E; Pratley RE; Blonde L; Svendsen CB; Donsmark M; Sesti G
Endocr Pract; 2013; 19(1):64-72. PubMed ID: 23186975
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Exenatide Plus Pioglitazone Vs Basal/Bolus Insulin in T2DM Patients With Very High HbA1c.
Abdul-Ghani M; Migahid O; Megahed A; DeFronzo RA; Zirie M; Jayyousi A
J Clin Endocrinol Metab; 2017 Jul; 102(7):2162-2170. PubMed ID: 28324038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]